Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy

Ilio Vitale, Antonella Sistigu, Gwenola Manic, Nils Petter Rudqvist, Zlatko Trajanoski, Lorenzo Galluzzi

Research output: Contribution to journalReview article

Abstract

Evolving neoplasms accumulate non-synonymous mutations at a high rate, potentially enabling the expression of antigenic epitopes that can be recognized by the immune system. Since they are not covered by central tolerance, such tumor neoantigens (TNAs) should be under robust immune control as they surge. However, genetic defects that impair cancer cell eradication by the immune system coupled with the establishment of local immunosuppression can enable TNA accumulation, which is generally associated with improved clinical sensitivity to various immunotherapies. Here, we explore how tumor-intrinsic factors and immunological processes shape the mutational and antigenic landscape of evolving neoplasms to influence clinical responses to immunotherapy, and propose strategies to achieve robust immunological control of the disease despite disabled immunosurveillance.

Original languageEnglish
Pages (from-to)396-416
Number of pages21
JournalTrends in Cell Biology
Volume29
Issue number5
DOIs
Publication statusPublished - May 2019

Fingerprint

Immunotherapy
Neoplasms
Immune System
Central Tolerance
Immunologic Monitoring
Intrinsic Factor
Immune System Diseases
Immunosuppression
Epitopes
Mutation

Keywords

  • adoptive cell transfer
  • antigen presentation
  • immune checkpoint blockers
  • mutational load
  • oncolytic virotherapy
  • tumor microenvironment

ASJC Scopus subject areas

  • Cell Biology

Cite this

Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. / Vitale, Ilio; Sistigu, Antonella; Manic, Gwenola; Rudqvist, Nils Petter; Trajanoski, Zlatko; Galluzzi, Lorenzo.

In: Trends in Cell Biology, Vol. 29, No. 5, 05.2019, p. 396-416.

Research output: Contribution to journalReview article

Vitale, Ilio ; Sistigu, Antonella ; Manic, Gwenola ; Rudqvist, Nils Petter ; Trajanoski, Zlatko ; Galluzzi, Lorenzo. / Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. In: Trends in Cell Biology. 2019 ; Vol. 29, No. 5. pp. 396-416.
@article{cdfc467957224ba9baa0b3041541ec7d,
title = "Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy",
abstract = "Evolving neoplasms accumulate non-synonymous mutations at a high rate, potentially enabling the expression of antigenic epitopes that can be recognized by the immune system. Since they are not covered by central tolerance, such tumor neoantigens (TNAs) should be under robust immune control as they surge. However, genetic defects that impair cancer cell eradication by the immune system coupled with the establishment of local immunosuppression can enable TNA accumulation, which is generally associated with improved clinical sensitivity to various immunotherapies. Here, we explore how tumor-intrinsic factors and immunological processes shape the mutational and antigenic landscape of evolving neoplasms to influence clinical responses to immunotherapy, and propose strategies to achieve robust immunological control of the disease despite disabled immunosurveillance.",
keywords = "adoptive cell transfer, antigen presentation, immune checkpoint blockers, mutational load, oncolytic virotherapy, tumor microenvironment",
author = "Ilio Vitale and Antonella Sistigu and Gwenola Manic and Rudqvist, {Nils Petter} and Zlatko Trajanoski and Lorenzo Galluzzi",
year = "2019",
month = "5",
doi = "10.1016/j.tcb.2019.01.003",
language = "English",
volume = "29",
pages = "396--416",
journal = "Trends in Cell Biology",
issn = "0962-8924",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy

AU - Vitale, Ilio

AU - Sistigu, Antonella

AU - Manic, Gwenola

AU - Rudqvist, Nils Petter

AU - Trajanoski, Zlatko

AU - Galluzzi, Lorenzo

PY - 2019/5

Y1 - 2019/5

N2 - Evolving neoplasms accumulate non-synonymous mutations at a high rate, potentially enabling the expression of antigenic epitopes that can be recognized by the immune system. Since they are not covered by central tolerance, such tumor neoantigens (TNAs) should be under robust immune control as they surge. However, genetic defects that impair cancer cell eradication by the immune system coupled with the establishment of local immunosuppression can enable TNA accumulation, which is generally associated with improved clinical sensitivity to various immunotherapies. Here, we explore how tumor-intrinsic factors and immunological processes shape the mutational and antigenic landscape of evolving neoplasms to influence clinical responses to immunotherapy, and propose strategies to achieve robust immunological control of the disease despite disabled immunosurveillance.

AB - Evolving neoplasms accumulate non-synonymous mutations at a high rate, potentially enabling the expression of antigenic epitopes that can be recognized by the immune system. Since they are not covered by central tolerance, such tumor neoantigens (TNAs) should be under robust immune control as they surge. However, genetic defects that impair cancer cell eradication by the immune system coupled with the establishment of local immunosuppression can enable TNA accumulation, which is generally associated with improved clinical sensitivity to various immunotherapies. Here, we explore how tumor-intrinsic factors and immunological processes shape the mutational and antigenic landscape of evolving neoplasms to influence clinical responses to immunotherapy, and propose strategies to achieve robust immunological control of the disease despite disabled immunosurveillance.

KW - adoptive cell transfer

KW - antigen presentation

KW - immune checkpoint blockers

KW - mutational load

KW - oncolytic virotherapy

KW - tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85061247338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061247338&partnerID=8YFLogxK

U2 - 10.1016/j.tcb.2019.01.003

DO - 10.1016/j.tcb.2019.01.003

M3 - Review article

C2 - 30765144

AN - SCOPUS:85061247338

VL - 29

SP - 396

EP - 416

JO - Trends in Cell Biology

JF - Trends in Cell Biology

SN - 0962-8924

IS - 5

ER -